ReveraGen BioPharma
US-based ReveraGen BioPharma is a clinical-stage company specializing in therapeutic drug development.
Founded
2008US-based ReveraGen BioPharma is a clinical-stage company specializing in therapeutic drug development.
ReveraGen BioPharma, founded in Silver Spring, United States, is a clinical-stage company specializing in the development of therapeutic drugs. The company's core mission is to innovate in steroid chemistry and pharmacodynamic biomarkers to create effective treatments for serious diseases. ReveraGen's flagship product, vamorolone, is designed to treat Duchenne Muscular Dystrophy (DMD) and other potential indications. The company focuses on leveraging advanced clinical trial designs and unique business models to accelerate drug development.
Notable figures associated with ReveraGen BioPharma include key management and board members who have extensive experience in pharmaceutical development and venture philanthropy. The company has achieved significant milestones, including successful clinical trials for vamorolone, which have demonstrated promising results in treating DMD. ReveraGen's innovative approach has garnered attention and support from various stakeholders, making a substantial impact on the therapeutic landscape for muscular dystrophies and potentially other conditions.
Companies similar to ReveraGen BioPharma include Denovo Biopharma, Reven Holdings, DMD Therapeutics and Vanqua Bio.
ReveraGen BioPharma was founded in 2008.
ReveraGen BioPharma's headquarters is located in Rockville, MD, US.
ReveraGen BioPharma's most recent funding round was for $800k (USD) in February 2018.
As of Feb 23, 2018, ReveraGen BioPharma has disclosed funding of $800k (USD). Undisclosed round amounts are excluded.
ReveraGen BioPharma has 75 employees as of Feb 5, 2024.
Vanqua Bio
vanquabio.com
